{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:14:06Z","timestamp":1783660446515,"version":"3.55.0"},"reference-count":67,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Targeted immunotherapies with biologics, small molecules, and CAR T-cell therapies have revolutionized treatment across autoimmune, chronic inflammatory, oncologic, and transplant-related conditions. However, they have also expanded the population of patients susceptible to opportunistic infections. Toxoplasma gondii (T. gondii), a globally prevalent parasite, has emerged as an underrecognized pathogen in this immunomodulated host population. Toxoplasmosis, in such patients, can occur either through reactivation of a chronic\/latent\/past infection or from an acute\/primary infection and may be severe and even fatal. We present here the recommendations for such patients from the Remington Lab, the National Reference Center for Toxoplasmosis in the US. Screening for Toxoplasma infections is needed at baseline prior to starting targeted immunotherapy to identify seropositive patients who would benefit from prophylaxis or pre-emptive strategies and seronegative patients who would benefit from measures to prevent primary\/acute infections. Prompt diagnosis of Toxoplasma disease (toxoplasmosis) with molecular tools (T. gondii PCR and\/or agnostic metagenomics next-generation sequencing), and prompt initiation of anti-Toxoplasma therapy, can be lifesaving and prevent permanent neurocognitive sequelae and vision loss. The immunomodulatory effects of these therapies persist for several months after discontinuation, thereby extending the window of vulnerability. T. gondii-seropositive women are at increased risk of vertical transmission, even if targeted immunotherapy was discontinued several months before conception. We make a call for education, guidelines, prospective registries, targeted research, and addition of toxoplasmosis risk in the Warnings section of drug leaflets (and particularly so for T. gondii-seropositive women who intend to conceive after having been on targeted immunotherapies).<\/jats:p>","DOI":"10.3390\/pathogens15070696","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:50:37Z","timestamp":1782867037000},"page":"696","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Hidden Risk of Toxoplasmosis in the Expanding Immunomodulated Host Population: A Call for Guidelines and Registries in Patients on Biologics, Small Molecules, and Cellular Therapies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3378-8071","authenticated-orcid":false,"given":"Jose G.","family":"Montoya","sequence":"first","affiliation":[{"name":"Dr Jack S Remington Laboratory for Specialty Diagnostics, United States National Reference Center for Toxoplasmosis, Sutter Health, Palo Alto Medical Foundation, Palo Alto, CA 94301, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Cho","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6494-886X","authenticated-orcid":false,"given":"Stephanie","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Inova Children\u2019s Hospital, Fairfax, VA 22031, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-5710","authenticated-orcid":false,"given":"Carlos A.","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina G.","family":"Contopoulos-Ioannidis","sequence":"additional","affiliation":[{"name":"Dr Jack S Remington Laboratory for Specialty Diagnostics, United States National Reference Center for Toxoplasmosis, Sutter Health, Palo Alto Medical Foundation, Palo Alto, CA 94301, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)","volume":"24","author":"Michielin","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cho, S.M., Montoya, J.G., and Contopoulos-Ioannidis, D.G. (2025). Toxoplasmosis in the Era of Targeted Immunotherapy: A Systematic Review of Emerging Cases Linked to Biologics and Small Molecules in Autoimmune Diseases, Oncology and Transplantation. Pathogens, 14.","DOI":"10.3390\/pathogens14101001"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Durieux, M.F., Lopez, J.G., Banjari, M., Passebosc-Faure, K., Brenier-Pinchart, M.P., Paris, L., Gargala, G., Berthier, S., Bonhomme, J., and Chemla, C. (2022). Toxoplasmosis in patients with an autoimmune disease and immunosuppressive agents: A multicenter study and literature review. PLoS Negl. Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010691"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"de Almeida, G.B., Cristovao, M., Pontinha, C., and Januario, G. (2022). Cerebral Toxoplasmosis as an Uncommon Complication of Biologic Therapy for Rheumatoid Arthritis: Case Report and Review of the Literature. Brain Sci., 12.","DOI":"10.3390\/brainsci12081050"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"ofy259","DOI":"10.1093\/ofid\/ofy259","article-title":"Acute Toxoplasma Dissemination With Encephalitis in the Era of Biological Therapies","volume":"5","author":"Gharamti","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/rheumatology\/ket364","article-title":"Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis","volume":"53","author":"Nardone","year":"2014","journal-title":"Rheumatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101885","DOI":"10.1016\/j.msard.2019.101885","article-title":"Cerebral toxoplasmosis in patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab","volume":"39","author":"Raquel","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1212\/NXI.0000000000000063","article-title":"Toxoplasmic encephalitis during mycophenolate mofetil immunotherapy of neuromuscular disease","volume":"2","author":"Bernardo","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1111\/bjh.16402","article-title":"Disseminated toxoplasmosis and haemophagocytic lymphohistiocytosis following chimeric antigen receptor T-cell therapy","volume":"189","author":"Kator","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.semarthrit.2006.08.004","article-title":"Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis","volume":"36","author":"Lassoued","year":"2007","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/ced.14198","article-title":"Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis","volume":"45","author":"Javadzadeh","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/bjophthalmol-2015-306801","article-title":"Real-time PCR using the 529 bp repeat element for the diagnosis of atypical ocular toxoplasmosis","volume":"100","author":"Steeples","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ajh.21589","article-title":"Progressive multifocal leukencephalopathy and cerebral toxoplasmosis in a patient with CLL","volume":"85","author":"Desmond","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/qjmed\/hcw197","article-title":"Sarcoidosis, neurotoxoplasmosis and golimumab therapy","volume":"109","author":"Misra","year":"2016","journal-title":"QJM"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.jinf.2006.04.013","article-title":"Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation","volume":"54","author":"Lim","year":"2007","journal-title":"J. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamainternmed.2013.374","article-title":"Cerebral toxoplasmosis after rituximab therapy","volume":"173","author":"Safa","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1080\/09273948.2024.2367656","article-title":"Coinfection Suspicion is Imperative in Immunosuppressed Patients with Suspected Infectious Uveitis and Inadequate Treatment Response: A Case Report","volume":"32","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1111\/jog.14973","article-title":"Congenital toxoplasmosis after adalimumab treatment before pregnancy","volume":"47","author":"Krull","year":"2021","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.idcr.2016.06.006","article-title":"Cerebral toxoplasmosis and anti-TNFalpha: A case report","volume":"5","author":"Cren","year":"2016","journal-title":"IDCases"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"NP113","DOI":"10.1177\/11206721231207513","article-title":"Ocular toxoplasmosis following anti-tumour necrosis factor-alpha therapy combined with oral methotrexate therapy: A case report and review of literature","volume":"34","author":"Patnaik","year":"2024","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/ICB.0b013e3182790dbd","article-title":"Acute unilateral toxoplasma retinochoroiditis associated with adalimumab, a tumor necrosis factor-alpha antagonist","volume":"7","author":"Radwan","year":"2013","journal-title":"Retin. Cases Brief. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1097\/RHU.0000000000001124","article-title":"Atypical Ocular Toxoplasmosis During Adalimumab Anti-Tumor Necrosis Factor Therapy for Rheumatoid Arthritis","volume":"26","author":"Walkden","year":"2020","journal-title":"J. Clin. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/ibd\/izaa105","article-title":"Severe Necrotising Toxoplasmic Retinochoroiditis in a Patient With Crohn\u2019s Disease in Use of Adalimumab and Azathioprine","volume":"26","author":"Biancardi","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.22551\/2024.42.1101.10278","article-title":"Active toxoplasma chorioretinitis in immunocompromised patients: A case series","volume":"11","author":"Kayabasi","year":"2024","journal-title":"Arch. Clin. Cases"},{"key":"ref_25","first-page":"283","article-title":"Acute toxoplasmosis infection in a patient with ankylosing spondylitis treated with adalimumab: A case report","volume":"62","author":"Azevedo","year":"2010","journal-title":"Reumatismo"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Vigilante, R., Izhar, R., Paola, R.D., De, A., Pollastro, R.M., Capolongo, G., Viceconte, G., and Simeoni, M. (2025). Toxoplasma Gondii Replication During Belatacept Treatment in Kidney Transplantation: A Case Report and a Review of the Literature. Genes, 16.","DOI":"10.3390\/genes16040391"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/tri.12853","article-title":"Late isolated ocular toxoplasmosis in a belatacept-treated kidney transplant patient","volume":"29","author":"Lanfranco","year":"2016","journal-title":"Transpl. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.arcped.2018.08.004","article-title":"Neonatal fever: A puzzling case","volume":"25","author":"Plantaz","year":"2018","journal-title":"Arch. Pediatr."},{"key":"ref_30","first-page":"e8547","article-title":"Cerebral Toxoplasmosis in a Rheumatoid Arthritis Patient on Immunosuppressive Therapy","volume":"12","author":"Hill","year":"2020","journal-title":"Cureus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2169\/internalmedicine.54.3977","article-title":"Cerebral toxoplasmosis in a patient on methotrexate and infliximab for rheumatoid arthritis","volume":"54","author":"Pulivarthi","year":"2015","journal-title":"Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Young, J.D., and McGwire, B.S. (2005). Infliximab and reactivation of cerebral toxoplasmosis. N. Engl. J. Med., 353, 1530\u20131531; discussion 1530\u20131531.","DOI":"10.1056\/NEJMc051556"},{"key":"ref_33","first-page":"5565575","article-title":"Concurrent Ocular and Cerebral Toxoplasmosis in a Liver Transplant Patient Treated with Anti-CD40 Monoclonal Antibody","volume":"2023","author":"Kiselinova","year":"2023","journal-title":"Case Rep. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jdcr.2020.01.005","article-title":"Toxoplasmosis in a patient receiving ixekizumab for psoriasis","volume":"6","author":"Lobo","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/WNL.0b013e3181bd114f","article-title":"Ocular toxoplasmosis during natalizumab treatment","volume":"73","author":"Zecca","year":"2009","journal-title":"Neurology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/bcp.14445","article-title":"Cerebral toxoplasmosis associated with treatment with rituximab, azathioprine and prednisone for dermatomyositis","volume":"87","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jdcr.2019.10.015","article-title":"Cerebral toxoplasmosis after rituximab for pemphigus vulgaris","volume":"6","author":"Lee","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1515\/raon-2014-0042","article-title":"Cerebral toxoplasmosis in a diffuse large B cell lymphoma patient","volume":"50","author":"Savsek","year":"2016","journal-title":"Radiol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00108-019-00727-6","article-title":"Neurological symptoms in a patient on anti-TNF therapy, methotrexate and prednisolone for rheumatoid arthritis","volume":"61","author":"Bach","year":"2020","journal-title":"Internist"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e230415","DOI":"10.1136\/bcr-2019-230415","article-title":"Severe acute toxoplasmosis infection following ustekinumab treatment in a patient with psoriasis vulgaris","volume":"12","author":"Muslimani","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e229946","DOI":"10.1136\/bcr-2019-229946","article-title":"Unexpected neurologic complications following a novel lymphoma treatment \u2019expected\u2019 to give rise to neurologic toxicity","volume":"12","author":"Kersten","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S1473-3099(19)30119-7","article-title":"Toxoplasmosis initially presenting as neurological sequelae of chimeric antigen receptor T-cell therapy","volume":"19","author":"Marzolini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jamaophthalmol.2014.1088","article-title":"Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy","volume":"132","author":"Rao","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.msard.2017.05.004","article-title":"Cerebral toxoplasmosis in an MS patient receiving Fingolimod","volume":"18","author":"Parrado","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/09273940903315792","article-title":"Bilateral toxoplasma retinochoroiditis in a patient with chronic myeloid leukemia treated with imatinib mesylate","volume":"18","author":"Basu","year":"2010","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/j.1432-2277.2010.01173.x","article-title":"Toxoplasma gondii primary infection in renal transplant recipients. Two case reports and literature review","volume":"24","author":"Martina","year":"2011","journal-title":"Transpl. Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e27446","DOI":"10.1002\/pbc.27446","article-title":"Toxoplasmosis and secondary Guillain-Barre associated with ruxolitinib as graft-versus-host disease treatment","volume":"66","author":"Molina","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e13616","DOI":"10.1111\/tid.13616","article-title":"Unusual presentation of toxoplasmosis with gastro-intestinal involvement in HLA non-identical stem cell transplantation","volume":"23","author":"Hoellinger","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJMc1302895","article-title":"Bilateral toxoplasmosis retinitis associated with ruxolitinib","volume":"369","author":"Goldberg","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaip.2019.08.024","article-title":"Trends and Disparities in Asthma Biologic Use in the United States","volume":"8","author":"Inselman","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_51","unstructured":"Koenig, T. (2025). Trends in Cost and Utilization of Biologic Medications for Rheumatologic Conditions: A Medicare Claims Study (2013\u20132022). Arthritis Rheumatol., 77, Available online: https:\/\/acrabstracts.org\/abstract\/trends-in-cost-and-utilization-of-biologic-medications-for-rheumatologic-conditions-a-medicare-claims-study-2013-2022\/."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4269\/ajtmh.17-0677","article-title":"Toxoplasma gondii Infection in the United States, 2011-2014","volume":"98","author":"Jones","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/d41573-025-00001-5","article-title":"2024 FDA approvals","volume":"24","author":"Mullard","year":"2025","journal-title":"Ature Rev. Drug Discov."},{"key":"ref_55","unstructured":"CDC (2025, December 11). Preventing Toxoplasmosis, Available online: https:\/\/www.cdc.gov\/toxoplasmosis\/prevention\/index.html."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0161-6420(02)00990-9","article-title":"Ocular toxoplasmosis: Clinical features and prognosis of 154 patients","volume":"109","author":"Berendschot","year":"2002","journal-title":"Ophthalmology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1471-0528.2004.00302.x","article-title":"Reactivation of ocular toxoplasmosis during pregnancy","volume":"112","author":"Garweg","year":"2005","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1590\/S0021-75572010000100015","article-title":"Congenital toxoplasmosis from a chronically infected woman with reactivation of retinochoroiditis during pregnancy","volume":"86","author":"Andrade","year":"2010","journal-title":"J. Pediatr."},{"key":"ref_59","unstructured":"(2025, December 11). Performance Characteristics DISQVER\u00ae Platform. Available online: https:\/\/noscendo.com\/de\/en\/physicians."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1038\/s41591-024-03275-1","article-title":"Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections","volume":"30","author":"Benoit","year":"2024","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1128\/JCM.01663-15","article-title":"Significance of a Positive Toxoplasma Immunoglobulin M Test Result in the United States","volume":"53","author":"Dhakal","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_62","first-page":"863","article-title":"Fine needle aspiration of myelolipoma of the adrenal gland. Report of a case with computed tomography","volume":"29","author":"Pinto","year":"1985","journal-title":"Acta Cytol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e13913","DOI":"10.1111\/eci.13913","article-title":"Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10-year study from the BIOPURE registry","volume":"53","author":"Fornaro","year":"2023","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_64","first-page":"1781","article-title":"Uncovering risk factors for adverse events and infections in rheumatoid arthritis and rheumatoid arthritis with interstitial lung disease under treatment with biologics or targeted synthetic DMARDs: Insights from the KOBIO Registry","volume":"42","author":"Kim","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"210278","DOI":"10.1183\/16000617.0278-2021","article-title":"Biologics in severe asthma: The role of real-world evidence from registries","volume":"31","author":"Paoletti","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00296-020-04774-3","article-title":"Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: Data from the German BIKER registry","volume":"41","author":"Thiele","year":"2021","journal-title":"Rheumatol. Int."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ritchlin, C.T., Stahle, M., Poulin, Y., Bagel, J., Chakravarty, S.D., Kafka, S., Srivastava, B., Langholff, W., and Gottlieb, A.B. (2019). Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. BMC Rheumatol., 3.","DOI":"10.1186\/s41927-019-0094-3"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/7\/696\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:27:46Z","timestamp":1783657666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/7\/696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":67,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["pathogens15070696"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15070696","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}